The patient’s experience is used too little in monitoring pharmacotherapy realisation
Increasing adherence to pharmacotherapy is one of the most significant ways to increase the cost-effectiveness of treatment – currently too many people quit their prescribed medication for a chronic disease. Therefore, the patient’s experience should not be ignored in studies investigating the effectiveness of pharmacotherapy, stresses Timo Purmonen, who is leading Oriola’s services related to market access and research of pharmaceuticals with marketing authorisation.
Is the patient the best expert on their treatment? This is a question we often get to respond to when we want to investigate how pharmacotherapy is realised as part of the patient’s daily routines. The patient does not necessarily have the best knowledge of various treatment options or which of them is medically the most suitable. However, the patient needs to understand why they have medication and how it is promoting their wellbeing.
According to research, a significant share of patients quit or take irregularly their medication prescribed for a chronic disease. There might be many different reasons behind this, which can only be found out by asking the patients themselves. Patient surveys can be used to investigate for example how pharmacotherapy affects a cancer patient’s quality of life, is the medicine administration device simple to use for an asthma patient, or what kind of support an inflammatory bowel disease (IBD) patient would need for their pharmacotherapy. Since only consumed medication helps, increasing adherence to treatment is one of the best ways to increase the effectiveness and cost-effectiveness of pharmacotherapy.